Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
OwnerPranob P. BHATTACHARYA, Jane WENG +1inventors
InventorsPranob P. BHATTACHARYA, Jane WENG, Fumitaka KINUGASA
Life of this patent
Estimating the term…
Abstract
The present invention provides a combination therapy for treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Claims33
A method for treating or preventing cancer in a patient, comprising administering to the patient an anti-CLDN18.2 antibody, a platinum compound, a fluoropyrimidine compound or precursor thereof and an immune checkpoint inhibitor selected from a PD-1 inhibitor and a PD-L1 inhibitor.
A method for inhibiting growth of a tumor in a patient having cancer, comprising administering to the patient an anti-CLDN18.2 antibody, a platinum compound, a fluoropyrimidine compound or precursor thereof and an immune checkpoint inhibitor selected from a PD-1 inhibitor and a PD-L1 inhibitor.
A medical preparation comprising an anti-CLDN18.2 antibody, a platinum compound, a fluoropyrimidine compound or precursor thereof and an immune checkpoint inhibitor selected from a PD-1 inhibitor and a PD-L1 inhibitor.
Dependencies are inferred from the claim text.